This case study explores how VeraSci's Innovation Lab used Embrace2 to assess the validity of digital biomarkers against established cognitive and functional endpoints indicating the onset of decline in Alzheimer's disease.
Learn more about integrating digital endpoints in your research with this fascinating case study
By clicking on Download you consent to being contacted by Empatica Inc. about its products and services and you agree to the terms and conditions stated in the privacy policy.